Siemens Healthineers joins Prostate Cancer Foundation Radiopharmaceutical Think Tank
What happened
The Prostate Cancer Foundation expanded its Radiopharmaceutical Think Tank, announcing its 2026-2027 agenda. Siemens Healthineers joined the program, along with Orano Med and Telix, at the EANM Annual Congress in Vienna, Austria. The Think Tank aims to accelerate the development and patient access of novel radiopharmaceutical drugs for cancer treatment.
From finanznachrichten.de
Why it matters
The initiative seeks to increase the adoption of radiopharmaceuticals as a major therapeutic platform in prostate cancer and other tumor types. This collaboration involves stakeholders, including manufacturers, regulators, treatment centers, and payers, working together to ensure patient access to these treatments.
From finanznachrichten.de
Who's involved
- Siemens HealthineersParticipates in the Prostate Cancer Foundation's strategic think tank.
- Prostate Cancer FoundationExpanded the Radiopharmaceutical Think Tank to address challenges in cancer treatment.
- European Association of Nuclear MedicineHosted the Think Tank program during its Annual Congress.
Keep exploring
The entities involved
-
Siemens Healthineers
German company
Nothing else this week.
-
Prostate Cancer Foundation
non-profit organization in the USA
Nothing else this week.